Recent Updates — NMTC

NeuroOne Medical Technologies reported preliminary fiscal 2026 product revenue of approximately $10.5 million, representing 15.6% year-over-year growth and landing at the top of its guidance range. Fourth-quarter revenue was approximately $3.8 million, up 38.4% from the prior year period. The company also announced it secured a record $4.5 million purchase order in September 2026, with $1.0 million shipped by quarter-end and the remaining $3.6 million expected to ship in fiscal 2027. Total open orders reached $5.4 million as of September 30, 2026. NeuroOne Medical Technologies Corporation is a medical technology company focused on surgical diagnosis and treatment of neurological disorders.

NeuroOne Medical Technologies Corporation reported fiscal third quarter 2026 results ending June 30, 2026. Product revenue increased 16% year-over-year to $2.0 million, while product gross margins expanded to a record 59.9%. The company received $2.7 million in new product orders, growing its backlog to $1.7 million. Total operating expenses rose to $3.6 million, resulting in a net loss of $2.0 million, or ($0.23) per basic share. Cash and cash equivalents decreased to $2.0 million from $6.6 million at the start of the fiscal year. The company raised an additional $1.0 million via its ATM program subsequent to quarter-end. NeuroOne operates in the medical technology industry, developing minimally invasive surgical diagnosis and treatment solutions for neurological disorders.

NeuroOne Medical Technologies Corporation filed an updated Prospectus Supplement to offer and sell up to $13.4 million of common stock through an at-the-market offering program with JonesTrading Institutional Services LLC. The company is a developer of medical technology solutions for neurological and neurological-related disorders.